Product Name

Etoposide

Name: Etoposide - LGM Pharma
SKU: 33419-42-0

CAS Number

33419-42-0

LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Etoposide

CAS Number:

33419-42-0

Indication:

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Mode of Action:

Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell.. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division.

Pharmacodynamics:

Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

Metabolism:

Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine.

Toxicity:

Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

IUPAC:

(10R, 11R, 15R, 16S)-16-{[(2R, 4aR, 6R, 7R, 8R, 8aS)-7, 8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3, 2-d][1, 3]dioxin-6-yl]oxy}-10-(4-hydroxy-3, 5-dimethoxyphenyl)-4, 6, 13-trioxatetracyclo[7.7.0.0, {3, 7}.0, {11, 15}]hexadeca-1(9), 2, 7-trien-12-one

ATC:

L01CB01

PubChem:

36462

DrugBank:

DB00773 (APRD00239)

Formula:

C₂₂H₂₈N₂O

Molecular Mass:

588.5566

Synonyms:

(-)-Etoposide Etoposidum [INN-Latin] trans-Etoposide

SMILES:

COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=CC3=C(OCO3)C=C12

AHFS Code:

10:00.0

InChi:

VJJPUSNTGOMMGY-MRVIYFEKSA-N

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Etoposide

33419-42-0

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product